Levi & Korsinsky, LLP: Cellectra Device Manufacturing Practices at Center of Inovio Pharmaceuticals Securities Litigation
Important Notice Regarding Alleged Medical Device Manufacturing Misrepresentations
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Inovio Pharmaceuticals, Inc. (NASDAQ: INO) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between October 10, 2023 and December 26, 2025.
Click here to learn more about this case
You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.
The Alleged CELLECTRA Device Manufacturing Deficiencies
The biotechnology sector relies heavily on medical device functionality for drug delivery systems. For Inovio, the CELLECTRA device is an integral component of its DNA medicine platform, used to help DNA medicines enter the body's cells for optimal effect. According to the lawsuit, the Company represented that its CELLECTRA devices were "validated and manufactured under Current Good Manufacturing Practices (cGMP)," yet allegedly concealed manufacturing issues with the single-use disposable administration component.
How Manufacturing Issues Allegedly Affected BLA Submission
The complaint alleges that manufacturing deficiencies with the CELLECTRA device component caused a full-year delay in the Company's Biologics License Application (BLA) submission timeline. Defendants had projected submission by the second half of 2024, but the lawsuit contends that undisclosed manufacturing problems forced postponement to mid-2025.
Key CELLECTRA Manufacturing Allegations for Shareholders
• The lawsuit alleges Defendants touted CELLECTRA devices as cGMP-validated while concealing manufacturing deficiencies
• According to the complaint, a manufacturing issue with the single-use disposable administration component was identified during routine testing
• The action contends the manufacturing issue stemmed from a plastic molded part within the array component
• The lawsuit alleges the undisclosed issues caused an approximate one-year delay in BLA submission
• According to the complaint, retesting of the CELLECTRA device was required, further extending timelines
The DNA Medicine Platform Factor
Inovio's proprietary DNA medicine platform comprises two components: DNA plasmids and the CELLECTRA device. The lawsuit contends that the integrity of the device component was critical to the Company's commercial transition, making accurate disclosure of manufacturing status material to investors.
"This case presents important questions about manufacturing disclosure obligations in the biotechnology sector," said Joseph E. Levi, Esq., managing partner of Levi & Korsinsky, LLP. "We are committed to pursuing justice for investors who relied on the company's public statements about its device manufacturing practices."
Get more information or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-7500.
ABOUT LEVI & KORSINSKY, LLP
Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report. Applications to serve as lead plaintiff must be filed by April 7, 2026.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
